免费获得国外相关药品，最快 1 个工作日回馈药物信息
Screening of Lysosomal Storage Disorders Diseases in Minority Groups
| Condition or disease | Intervention/treatment |
|---|---|
| Lysosomal Storage Diseases | Diagnostic Test: Enzyme assay and molecular sequencing |
Lysosomes are small, cytoplasmic organelles that contain several acid hydrolase enzymes. These enzymes break down foreign materials and cellular debris allowing the lysosomes to act as recycling centers for the cells. Following DNA transcription, lysosomal enzymes are produced in the endoplasmic reticulum and targeted to lysosomes by specific recognition markers. If one of the enzymes is absent or if its function is diminished due to either an altered amino acid sequence of the protein or defective intracellular trafficking, the macromolecules metabolized by the specific enzyme will gradually accumulate in the lysosomes. Abnormal substrate storage leads to cellular dysfunction followed by cell death ultimately manifesting as tissue damage and organ failure.
More than 50 metabolic disorders resulting from defective lysosomal enzyme function have been described and are classified as lysosomal storage disorders (LSDs). Although individually uncommon (less than 1 in 100,000), the combined incidence of this group of genetic disorders is about 1 in 5,000 to 1 in 10,000. The prevalence might be even higher than predicted due to undiagnosed instances or misdiagnosis of milder cases.
Most of LSDs are inherited in an autosomal recessive manner except two disorders: Fabry disease and Hunter syndrome, which are X chromosome linked. Two healthy carriers of the same autosomal recessive disease may have an affected child. Usually the carriers are unaware of their carrier status prior to screening or until they have a sick child. These disorders are more common in communities with high consanguinity and where cousin marriages are allowed. In the case of X-linked diseases, the mutant gene is passed down from one generation to the next one in a specific way. If a male has an abnormal copy of the specific gene, he will show the typical presentation of the disease. If a woman has an abnormal copy of the specific gene, she may develop some milder symptoms of the disease due to random X- inactivation.
Screening for LSDs is performed by measuring enzymatic activity in peripheral blood. The most cost effective and convenient way is to use dried filter paper blood spots. A positive screening result has to be followed by a confirmatory enzymatic testing using white blood cells, plasma or cultured skin fibroblasts and/or DNA mutation analysis. The importance of screening for LSDs has been recognized by several state governments as these tests are being included in many newborn screening programs. Although newborn screening helps to identify patients early on, there is still an unmet need for population screening and for identifying patients with reversible tissue damage. LSDs cause serious and progressive problems with multiple body systems. Therapy is available and is promising in most cases. Importantly, patients with LSDs require thorough management plans for their complex health issues.
| Study Type : | Observational |
| Estimated Enrollment : | 100000 participants |
| Observational Model: | Ecologic or Community |
| Time Perspective: | Prospective |
| Official Title: | Enzymatic and Genotypic Screening of Lysosomal Storage Diseases in Minority Groups |
| Actual Study Start Date : | March 17, 2016 |
| Estimated Primary Completion Date : | December 2019 |
| Estimated Study Completion Date : | December 2019 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
Screen population
The study population will comprise of patients of healthcare institutions in the Washington, D.C. metro area including but not limited to hospitals, clinics, and doctor's offices.
|
Diagnostic Test: Enzyme assay and molecular sequencing
Enzyme assay and molecular sequencing on relevant samples conducted from left over blood samples
|
- Enzyme activity analysis to identify subjects with Lysosomal storage disorders [ Time Frame: 5 years ]To identify patients with LSDs using enzymatic activity specific to individual lysosomal storage disorders using left-over blood of blood samples collected as part of standard clinical care.
- Genotypic analysis of subjects with abnormal enzyme activity [ Time Frame: 5 years ]Samples from subjects with abnormally low enzyme activity will be used for targeted sequencing analysis to diagnose any pathologic mutations.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
-
To be enrolled in this study the subject must meet the following (inclusion) criteria:
- Subject is greater than or equal to 1 day of age and less than or equal to 100 years of age
- Subject is managed by a physician in the Washington, D.C and Richmond, VA metro area
- Subject is getting blood work as part of standard clinical care and there is at least 60 uL blood remained in a tube after all clinical tests were run
Exclusion Criteria:
-
subjects must not meet any of the following (exclusion) criteria:
- Absolute contraindication for blood drawing
- Subject cannot be traced back by the referring physician upon a positive screening result
| United States, Virginia | |
| LDRTC | |
| Fairfax, Virginia, United States, 22030 | |
| Principal Investigator: | Renuka Limgala, PhD | LDRTC | |
| Principal Investigator: | Margarita M Ivanova, PhD | LDRTC | |
| Principal Investigator: | Ozlem Goker-Alpan, MD | LDRTC |
| Tracking Information | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| First Submitted Date | January 18, 2019 | |||||||||
| First Posted Date | January 22, 2019 | |||||||||
| Last Update Posted Date | January 22, 2019 | |||||||||
| Actual Study Start Date | March 17, 2016 | |||||||||
| Estimated Primary Completion Date | December 2019 (Final data collection date for primary outcome measure) | |||||||||
| Current Primary Outcome Measures |
|
|||||||||
| Original Primary Outcome Measures | Same as current | |||||||||
| Change History | No Changes Posted | |||||||||
| Current Secondary Outcome Measures | Not Provided | |||||||||
| Original Secondary Outcome Measures | Not Provided | |||||||||
| Current Other Pre-specified Outcome Measures | Not Provided | |||||||||
| Original Other Pre-specified Outcome Measures | Not Provided | |||||||||
| Descriptive Information | ||||||||||
| Brief Title | Screening of Lysosomal Storage Disorders Diseases in Minority Groups | |||||||||
| Official Title | Enzymatic and Genotypic Screening of Lysosomal Storage Diseases in Minority Groups | |||||||||
| Brief Summary | Aim is to undertake a screening study that identifies undiagnosed patients with LSDs and determine the prevalence of these diseases with special focus on underrepresented minority groups. | |||||||||
| Detailed Description |
Lysosomes are small, cytoplasmic organelles that contain several acid hydrolase enzymes. These enzymes break down foreign materials and cellular debris allowing the lysosomes to act as recycling centers for the cells. Following DNA transcription, lysosomal enzymes are produced in the endoplasmic reticulum and targeted to lysosomes by specific recognition markers. If one of the enzymes is absent or if its function is diminished due to either an altered amino acid sequence of the protein or defective intracellular trafficking, the macromolecules metabolized by the specific enzyme will gradually accumulate in the lysosomes. Abnormal substrate storage leads to cellular dysfunction followed by cell death ultimately manifesting as tissue damage and organ failure. More than 50 metabolic disorders resulting from defective lysosomal enzyme function have been described and are classified as lysosomal storage disorders (LSDs). Although individually uncommon (less than 1 in 100,000), the combined incidence of this group of genetic disorders is about 1 in 5,000 to 1 in 10,000. The prevalence might be even higher than predicted due to undiagnosed instances or misdiagnosis of milder cases. Most of LSDs are inherited in an autosomal recessive manner except two disorders: Fabry disease and Hunter syndrome, which are X chromosome linked. Two healthy carriers of the same autosomal recessive disease may have an affected child. Usually the carriers are unaware of their carrier status prior to screening or until they have a sick child. These disorders are more common in communities with high consanguinity and where cousin marriages are allowed. In the case of X-linked diseases, the mutant gene is passed down from one generation to the next one in a specific way. If a male has an abnormal copy of the specific gene, he will show the typical presentation of the disease. If a woman has an abnormal copy of the specific gene, she may develop some milder symptoms of the disease due to random X- inactivation. Screening for LSDs is performed by measuring enzymatic activity in peripheral blood. The most cost effective and convenient way is to use dried filter paper blood spots. A positive screening result has to be followed by a confirmatory enzymatic testing using white blood cells, plasma or cultured skin fibroblasts and/or DNA mutation analysis. The importance of screening for LSDs has been recognized by several state governments as these tests are being included in many newborn screening programs. Although newborn screening helps to identify patients early on, there is still an unmet need for population screening and for identifying patients with reversible tissue damage. LSDs cause serious and progressive problems with multiple body systems. Therapy is available and is promising in most cases. Importantly, patients with LSDs require thorough management plans for their complex health issues. |
|||||||||
| Study Type | Observational | |||||||||
| Study Design | Observational Model: Ecologic or Community Time Perspective: Prospective |
|||||||||
| Target Follow-Up Duration | Not Provided | |||||||||
| Biospecimen | Not Provided | |||||||||
| Sampling Method | Non-Probability Sample | |||||||||
| Study Population | The study population will comprise of patients of healthcare institutions in the Washington, D.C. and Richmond, Virginia areas including but not limited to hospitals, clinics, and doctor's offices. | |||||||||
| Condition | Lysosomal Storage Diseases | |||||||||
| Intervention | Diagnostic Test: Enzyme assay and molecular sequencing
Enzyme assay and molecular sequencing on relevant samples conducted from left over blood samples
|
|||||||||
| Study Groups/Cohorts | Screen population
The study population will comprise of patients of healthcare institutions in the Washington, D.C. metro area including but not limited to hospitals, clinics, and doctor's offices.
Intervention: Diagnostic Test: Enzyme assay and molecular sequencing
|
|||||||||
| Publications * | Not Provided | |||||||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||||||||
| Recruitment Information | ||||||||||
| Recruitment Status | Unknown status | |||||||||
| Estimated Enrollment |
100000 | |||||||||
| Original Estimated Enrollment | Same as current | |||||||||
| Estimated Study Completion Date | December 2019 | |||||||||
| Estimated Primary Completion Date | December 2019 (Final data collection date for primary outcome measure) | |||||||||
| Eligibility Criteria |
Inclusion Criteria:
Exclusion Criteria:
|
|||||||||
| Sex/Gender |
|
|||||||||
| Ages | Child, Adult, Older Adult | |||||||||
| Accepts Healthy Volunteers | Yes | |||||||||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||||||||
| Listed Location Countries | United States | |||||||||
| Removed Location Countries | ||||||||||
| Administrative Information | ||||||||||
| NCT Number | NCT03812042 | |||||||||
| Other Study ID Numbers | 16-LDRTC-04 | |||||||||
| Has Data Monitoring Committee | No | |||||||||
| U.S. FDA-regulated Product |
|
|||||||||
| IPD Sharing Statement |
|
|||||||||
| Responsible Party | Lysosomal and Rare Disorders Research and Treatment Center, Inc. | |||||||||
| Study Sponsor | Lysosomal and Rare Disorders Research and Treatment Center, Inc. | |||||||||
| Collaborators | Not Provided | |||||||||
| Investigators |
|
|||||||||
| PRS Account | Lysosomal and Rare Disorders Research and Treatment Center, Inc. | |||||||||
| Verification Date | January 2019 | |||||||||